Affimed (AFMD) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Affimed Revenue Highlights


Latest Revenue (Y)

$8.28M

Latest Revenue (Q)

$155.00K

Main Segment (Y)

Collaboration

Main Geography (Y)

USA

Affimed Revenue by Period


Affimed Revenue by Year

DateRevenueChange
2023-12-31$8.28M-79.99%
2022-12-31$41.35M2.45%
2021-12-31$40.37M42.33%
2020-12-31$28.36M32.58%
2019-12-31$21.39M-9.88%
2018-12-31$23.73M1080.85%
2017-12-31$2.01M-68.17%
2016-12-31$6.31M-16.50%
2015-12-31$7.56M123.60%
2014-12-31$3.38M-33.52%
2013-12-31$5.09M333.67%
2012-12-31$1.17M-

Affimed generated $8.28M in revenue during NA 2023, up -79.99% compared to the previous quarter, and up 34.86% compared to the same period a year ago.

Affimed Revenue by Quarter

DateRevenueChange
2024-03-31$155.00K-62.47%
2023-12-31$413.00K-78.95%
2023-09-30$1.96M41.15%
2023-06-30$1.39M-69.18%
2023-03-31$4.51M-59.58%
2022-12-31$11.16M-25.05%
2022-09-30$14.89M103.92%
2022-06-30$7.30M-8.81%
2022-03-31$8.01M-22.56%
2021-12-31$10.34M19.35%
2021-09-30$8.66M-10.77%
2021-06-30$9.71M-16.74%
2021-03-31$11.66M19.63%
2020-12-31$9.75M-7.58%
2020-09-30$10.54M259.41%
2020-06-30$2.93M-42.86%
2020-03-31$5.13M30.76%
2019-12-31$3.93M86.73%
2019-09-30$2.10M-47.53%
2019-06-30$4.01M-64.70%
2019-03-31$11.35M-50.09%
2018-12-31$22.75M7333.66%
2018-09-30$306.00K104.00%
2018-06-30$150.00K-71.80%
2018-03-31$532.00K-16.35%
2017-12-31$636.00K36.19%
2017-09-30$467.00K-8.07%
2017-06-30$508.00K27.32%
2017-03-31$399.00K-70.90%
2016-12-31$1.37M46.16%
2016-09-30$938.00K-54.66%
2016-06-30$2.07M6.87%
2016-03-31$1.94M16.70%
2015-12-31$1.66M43.64%
2015-09-30$1.16M-47.74%
2015-06-30$2.21M-12.92%
2015-03-31$2.54M3033.33%
2014-12-31$81.00K-95.72%
2014-09-30$1.89M175.40%
2014-06-30$687.00K-4.85%
2014-03-31$722.00K-84.39%
2013-12-31$4.63M2321.47%
2013-09-30$191.00K-4.98%
2013-06-30$201.00K187.14%
2013-03-31$70.00K-

Affimed generated $155.00K in revenue during Q1 2024, up -62.47% compared to the previous quarter, and up 1.39% compared to the same period a year ago.

Affimed Revenue Breakdown


Affimed Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Collaboration$7.76M$41.20M$39.30M--
Service$510.00K$155.00K$1.06M--
Services---$605.00K$1.71M
Collaboration Service---$27.75M$19.68M

Affimed's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration (93.84%), and Service (6.16%).

Quarterly Revenue by Product

Product/ServiceDec 23Jun 23Jun 22Jun 21Jun 20Jun 19
Collaboration$6.55M$1.22M$7.28M---
Service$335.00K$175.00K$17.00K---
Services---$222.00K$141.00K$325.00K
Collaboration Service---$9.48M$2.79M$3.68M

Affimed's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Collaboration (95.13%), and Service (4.87%).

Affimed Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
USA$8.27M$41.20M$39.62M--
Germany$5.00K$152.00K$742.00K--
Europe---$2.00K$1.65M
U---$28.16M$19.75M
D---$194.00K-

Affimed's latest annual revenue breakdown by geography, as of Dec 23: USA (99.94%), and Germany (0.06%).

Quarterly Revenue by Country

CountryDec 23Jun 23Jun 22Jun 21Jun 20Jun 19
USA$6.88M$1.39M$7.29M---
Germany--$14.00K---
U---$9.48M$2.93M$3.68M
D---$222.00K--
Europe-----$325.00K

Affimed's latest quarterly revenue breakdown by geography, as of Dec 23: USA (100.00%).

Affimed Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
AGENAgenus$156.31M$23.51M
ADCTADC Therapeutics SA$69.56M$17.03M
ADAPAdaptimmune Therapeutics$60.28M$128.37M
PIRSPieris Pharmaceuticals$42.81M-
MREOMereo BioPharma Group$10.00M-
AFMDAffimed$8.28M$155.00K
CRVSCorvus Pharmaceuticals--
APTOAptose Biosciences--
XFORX4 Pharmaceuticals-$563.00K
PDSBPDS Bio--
DAWNDay One Biopharmaceuticals-$20.07M
INZYInozyme Pharma--
LPTXLeap Therapeutics--
ELEVElevation Oncology--
TERNTerns Pharmaceuticals--
HEPAHepion Pharmaceuticals--
EFTReFFECTOR Therapeutics--

AFMD Revenue FAQ


Affimed's yearly revenue for 2023 was $8.28M, representing a decrease of -79.99% compared to 2022. The company's yearly revenue for 2022 was $41.35M, representing an increase of 2.45% compared to 2021. AFMD's yearly revenue for 2021 was $40.37M, representing an increase of 42.33% compared to 2020.

Affimed's quarterly revenue for Q1 2024 was $155K, a -62.47% decrease from the previous quarter (Q4 2023), and a -96.56% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $413K, a -78.95% decrease from the previous quarter (Q3 2023), and a -96.30% decrease year-over-year (Q4 2022). AFMD's quarterly revenue for Q3 2023 was $1.96M, a 41.15% increase from the previous quarter (Q2 2023), and a -86.82% decrease year-over-year (Q3 2022).

Affimed's revenue growth rate for the last 3 years (2021-2023) was -79.50%, and for the last 5 years (2019-2023) was -61.32%.

Affimed's revenue streams in c 23 are Collaboration, and Service. Collaboration generated $7.76M in revenue, accounting 93.84% of the company's total revenue, down -81.15% year-over-year. Service generated $510K in revenue, accounting 6.16% of the company's total revenue, up 229.03% year-over-year.

For the fiscal year ending Dec 23, the largest source of revenue of Affimed was Collaboration. This segment made a revenue of $7.76M, representing 93.84% of the company's total revenue.